Skip to main content
GRAL
NASDAQ Industrial Applications And Services

GRAIL Reports Strong 2025 Preliminary Results, $904M Cash, and Extends Runway into 2030

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$97.86
Mkt Cap
$3.736B
52W Low
$16.56
52W High
$115.76
52W Position info
491% above low
Off High info
15% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

GRAL has more than doubled off its 52-week low of $16.56 on light trading volume (0.2× avg).

Summary

GRAIL, Inc. announced preliminary Q4 and full-year 2025 financial results, reporting a strong cash position of $904 million and extending its cash runway into 2030, supported by recent capital raises and reduced cash burn.


Key Events · Earnings and Guidance · GRAL

  • Strong Cash Position

    Reported $904 million in unrestricted cash, cash equivalents, and short-term marketable securities as of year-end 2025.

  • Extended Cash Runway

    Projected cash runway into 2030, significantly de-risking future operations and development.

  • Reduced Cash Burn

    2025 cash burn decreased to $274 million from $579 million in 2024, with 2026 guidance for cash burn below $300 million.

  • Significant Capital Raises

    Secured $435 million in Q4 2025 through a $325 million private placement, a $110 million strategic investment from Samsung, and ATM sales.


Analysis · GRAL · Industrial Applications And Services

This 8-K filing provides a comprehensive positive update for GRAIL, Inc. The company's preliminary 2025 financial results show solid revenue growth and a significant reduction in cash burn, demonstrating improved financial efficiency. The substantial cash position of $904 million, bolstered by $435 million in Q4 capital raises, provides a long runway into 2030, significantly de-risking the company's operations and future development plans. This financial stability is crucial as GRAIL progresses towards its modular PMA submission for the Galleri test in Q1 2026 and anticipates full data readouts from key clinical trials in mid-2026. The extended runway allows the company to focus on commercial expansion and regulatory milestones without immediate financing pressures.

At the time of this filing, GRAL was trading at $97.86 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $16.56 to $115.76. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GRAL - Latest Insights

GRAL
Jul 14, 2026, 6:17 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $71.80
Real-time Price: $67.35 info
Change: -$4.45 (-6%) info
Market Cap: $2.765B info
GRAL
Jun 29, 2026, 3:31 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $68.50
Real-time Price: $67.35 info
Change: -$1.15 (-2%) info
Market Cap: $2.765B info
GRAL
May 30, 2026, 8:14 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $73.00
Real-time Price: $67.35 info
Change: -$5.65 (-8%) info
Market Cap: $2.765B info
GRAL
May 07, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $61.72
Real-time Price: $67.35 info
Change: +$5.63 (+9%) info
Market Cap: $2.765B info
GRAL
May 05, 2026, 4:22 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $53.00
Real-time Price: $67.35 info
Change: +$14.35 (+27%) info
Market Cap: $2.765B info